Clinical Trial Update: An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 open trial evaluating the tolerability of AVANZ Cupressus Immunotherapy for allergic rhinoconjunctivitis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• AVANZ Cupressus Immunotherapy

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinoconjunctivitis | Phase 2 | Status: COMPLETED